On April 17, GLONGHUI (688105.SH) announced that the first quarter of 2024 achieved operating revenue of 30,000 million yuan to 315 million yuan. Compared with the same period of the previous year (statutory disclosure data), it will increase by -219 million yuan to 12.81 million yuan, an increase of -0.7% to 4% over the previous year. Net profit attributable to owners of the parent company was 4.5 million yuan to 5.5 million yuan in the first quarter of 2024. Compared with the same period last year (statutory disclosure data), it will increase 55.12 million yuan to 56.12 million yuan, an increase of 109% to 111% over the previous year, turning a loss into a profit. In the first quarter of 2024, net profit attributable to the owners of the parent company was 16.7 million yuan to -15.7 million yuan. Compared with the same period of the previous year (statutory disclosure data), it will increase by 58.42 million yuan to 59.42 million yuan, and the loss margin narrowed drastically.
After the 2023 layout, the company's life science business extraction, new product lines such as cells, and proteins were further improved. With the existing mature sales system, customer unit prices and market coverage increased rapidly, and related sales revenue increased significantly during the reporting period. With the continuous optimization of business processes and the gradual improvement of marketing networks and supply chain construction, the number of effective customer visits and global delivery capabilities has been effectively improved, and international business sales revenue has increased significantly over the same period last year. Furthermore, due to factors such as commercialization of respiratory pathogen detection projects in the company's in vitro diagnosis business, further increase in market share of new drug development reagents in the biomedical business, and receipt of milestone payments for antibody discovery and commercialization projects, the scale of the company's regular business revenue increased further during the reporting period.